Globus Medical Inc. Class A Common Stock vs Taiwan Semiconductor Mfg. Co. Ltd. — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Taiwan Semiconductor Mfg. Co. Ltd. trades at $422.98 (market cap $2.02T). The key difference: Taiwan Semiconductor Mfg. Co. Ltd. is far larger — about 197.1× Globus Medical Inc. Class A Common Stock's market cap, and Taiwan Semiconductor Mfg. Co. Ltd. pays a 0.91% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Taiwan Semiconductor Mfg. Co. Ltd. for 111 Days on average.
| GMED | TSM | |
|---|---|---|
Market Cap | $10.25B | $2.02T |
Volume | 1,108,124 | 8,566,236 |
Sector | Health | Technology |
52-Week High | $96.82 | $485.80 |
52-Week Low | $58.33 | $275.06 |
Typical Hold Time | 0 Days | 111 Days |
Enterprise Value | $9.76B | $1.94T |
Dividend Yield | — | 0.91% |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
TSMC (TSM) trades at $445.12, up 0.17% on the day, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates for the last three quarters, with Q3 2026 results pending. Revenue and net income have shown robust growth, with 2025 revenue at $3.81T and net income at $1.70T. Analyst sentiment is overwhelmingly positive, with a consensus price target of $578.43, representing significant upside. Recent news highlights TSMC's pivotal role in AI chip manufacturing and upcoming dividend payments.
The outlook for TSM is favorable, driven by strong earnings momentum, high profitability margins, and its dominant position in semiconductor manufacturing. Key opportunities include continued AI-driven demand and technological leadership. Risks involve geopolitical tensions, competitive pressures, and market volatility. The stock presents a compelling long-term investment case supported by analyst optimism and solid financial health.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →Taiwan Semiconductor Manufacturing Company, or TSMC, is the world's largest dedicated chip foundry, with over 57% market share in 2021 per Gartner. TSMC was founded in 1987 as a joint venture of Philips, the government of Taiwan, and private investors. It went public as an ADR in the U.S. in 1997. TSMC's scale and high-quality technology allow the firm to generate solid operating margins, even in the highly competitive foundry business. Furthermore, the shift to the fabless business model has created tailwinds for TSMC. The foundry leader has an illustrious customer base, including Apple, AMD and Nvidia, that looks to apply cutting-edge process technologies to its semiconductor designs.
Read more on TSM →